Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Nov;34(11):2148-51.
doi: 10.1128/AAC.34.11.2148.

Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats

Affiliations

Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats

A Anadón et al. Antimicrob Agents Chemother. 1990 Nov.

Abstract

The effect of ciprofloxacin pretreatment on the pharmacokinetics and metabolism of antipyrine in male rats was studied. The animals received oral antipyrine (20 mg/kg of body weight) with and without ciprofloxacin pretreatment (40 mg/kg orally once a day for 8 days). The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively. The urinary excretions of norantipyrine, 4-hydroxyantipyrine, and 3-hydroxymethylantipyrine decreased by 73, 43, and 54%, respectively (P less than 0.001), in the 96 h after ciprofloxacin treatment. In addition, the rate constants for formation of each of these metabolites were significantly decreased, by an average of approximately 75%. These results suggest that ciprofloxacin is capable of inhibiting oxidative metabolism. This finding could be of clinical significance for drugs that are highly dependent of metabolic pathways, such as those inhibited in this study.

PubMed Disclaimer

Similar articles

References

    1. Br J Clin Pharmacol. 1986 Dec;22(6):677-83 - PubMed
    1. Antimicrob Agents Chemother. 1990 Apr;34(4):594-9 - PubMed
    1. Br J Pharmacol Chemother. 1967 Feb;29(2):136-49 - PubMed
    1. J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75 - PubMed
    1. Pharmacology. 1979;18(4):210-23 - PubMed

Publication types

LinkOut - more resources